VERICEL CORPORATION Contract Liability (Deferred Revenue)
VERICEL CORPORATION (VCEL) had Contract Liability (Deferred Revenue) of $534.00 thousand as of 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2018-11-06
- 2018-09-30: Contract with Customer, Liability, Current $534.00K.
- 2017-12-31: Contract with Customer, Liability, Current $420.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2018-09-30 | $534.00K 10-Q · filed 2018-11-06 |
| 2017-12-31 | $420.00K 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |